AUTHOR: Jodi

Marks the eighth advisor to growing KOL program to build strong body of clinical evidence and support US commercialization Aclarion to participate in upcoming SPINEWEEK 2023   Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location […]

NociscanTM is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological pain. Nociscan provides decision support to help bridge a major diagnostic void. Robert Eastlack, MD will speak to his real-world experience using Nociscan to effectively evaluate CLBP.   Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare […]

Director of Endoscopic Spine Surgery at the University of Miami Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Gregory Basil, MD, Director of Endoscopic Spine Surgery at […]

Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that George Frey MD, Founder of the Colorado Comprehensive Spine Institute will advise the company as a key opinion leader […]

Broomfield, CO. In a recent publication of the Wall Street Transcript, Jeff Thramann, Aclarion’s Executive Director and Executive Chairman, was featured in an interview discussing the value and opportunity of the Nociscan solution in the chronic low back pain (cLBP) market. Read the full article here. Aclarion Wall Street Transcript Article

Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Dr. Christopher Ames, Director of Spinal Deformity and Spine Tumor Surgery and Co-Director of the Combined High Risk Spine […]

Development of this program supports Aclarion’s commitment to lead with strong clinical evidence and engage the payer community through key opinion leader advocacy.   Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low […]

Dr. Uribe is the fourth national KOL to join the Aclarion team this year. Development of this program supports Aclarion’s commitment to lead with strong clinical evidence and engage the payer community through key opinion leader advocacy. December 19, 2022, Broomfield, CO – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology […]

Strengthens portfolio by addressing the anaerobic bacteria that can seed into the intervertebral disc, proliferate, and accelerate painful disc degeneration. Successful commercialization of IP holds the promise of giving physicians better data to make the critical decision as to whether antibiotic therapy or surgery is the preferred treatment option.   Aclarion, Inc., (“Aclarion” or the […]

Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Sigurd Berven M.D., Chief of Spine Service, Orthopaedic Surgery at University of California at San Francisco will advise the […]